Trial Profile
Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension (The OVATION Study)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2023
Price :
$35
*
At a glance
- Drugs Iloprost (Primary) ; Nitric oxide
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms OVATION
- 24 May 2023 Results (n=23) to compare degree of vasoreactivity with iloprost and iNO and assess how this impacted subsequent clinical course, presented at the 119th International Conference of the American Thoracic Society.
- 06 Mar 2023 Primary endpoint has been met. (Change in invasively measured pulmonary artery pressures after challenge with NO and iloprost), as per Results presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation
- 06 Mar 2023 Results presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation